Article
SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition.
PloS one - 1 Jan 2013
Hanson Jesse E, La Hank, Plise Emile, Chen Yung-Hsiang, Ding Xiao, Hanania Taleen, Sabath Emily V, Alexandrov Vadim, Brunner Dani, Leahy Emer, Steiner Pascal, Liu Lichuan, Scearce-Levie Kimberly, Zhou Qiang
Abstract excerpt
Suberoylanilide hydroxamic acid (SAHA) is an inhibitor of histone deacetylases (HDACs) used for the treatment of cutaneous T cell lymphoma (CTCL) and under consideration for other indications. In vivo studies suggest reducing HDAC function can enhance synaptic function and memory, raising the pos...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
